Prevention With Joel Kahn, MD

Cardiology

Dr. Kahn is a summa cum laude graduate of the University of Michigan School of Medicine. He practices cardiology in Detroit, is a clinical professor of medicine at Wayne State University School of Medicine, and specializes in vegan nutrition and heart disease reversal.


Breast Cancer Prevention With Whole Food Plant Diets

Dear readers,

2025 is looking like an upbeat and health-focused year (#MAHA), and it is helpful to start with an excellent article on breast cancer prevention through whole food plant-based diets. The next article confirms that the technology of coronary CT angiography can play a meaningful role in patient outcomes, according to the SCOT-Heart Study. Want a healthier liver? Eat dark green leafy vegetables. Legumes like lentils are so ‘carby,’ but they lower cholesterol and blood sugar in a randomized controlled trial (RCT).

The American Heart Association’s Life’s Essential 8 not only predicts heart health but also bone health. Trying the keto or carnivore diet? You’d better check your lab work a month later, as a case study reports a horrible outcome from that diet. Muscle infiltration with fat droplets (from a high saturated fat diet) not only induces insulin resistance (lipotoxicity) but also harms cardiovascular health and function. Finally, the future of therapies for lipoprotein(a) is bright, with a new Rx anticipated later this year.

Be well,

Joel Kahn, MD, FACC


Articles
  • Mashup Score: 0
    Tweet Tweets with this article
    • People with pockets of fat hidden inside their muscles are at a higher risk of dying or being hospitalised from a heart attack or heart failure, regardless of their body mass index, according to research published in the European Heart Journal [1] today (Monday).

      This ‘intermuscular’ fat is highly prized in beef steaks for cooking. However, little is known about this type of body fat in humans, and its impact on health. This is the first study to comprehensively investigate the effects of fatty muscles on heart disease.

  • Mashup Score: 0
    Tweet Tweets with this article
    • Muvalaplin and Zerlasiran are at the rear of the pack in the years-long timeline of clinical drug trials. All five new drug candidates have been shown to be safe in small early studies and to effectively lower Lp(a) levels. But what the FDA will ultimately look at is whether those results hold among thousands of people in very large phase III trials.